Investigate the utility of vincristine pharmacokinetic and pharmacogenetic biomarkers to predict MRD status and toxicity in children with acute lymphoblastic leukaemiaDr Sujith Samarasinghe, Great Ormond Street Hospital
T cell receptor gene therapy: novel strategies for children with cancer using engineered cord blood T cellsProfessor Waseem Qasim, UCL Institute of Child Health
Evaluation of CCL17 as a diagnostic biomarker for classical Hodgkin lymphomaProfessor Ruth Jarrett, University of Glasgow Garscube Estate
Development of an anti c-kit antibody to improve outcomes after stem cell transplantation for acute myeloid leukaemiaProfessor Persis Amrolia, UCL Institute of Child Health
The role of ACVR1/ALK2 mutations in diffuse intrinsic pontine gliomaProfessor Chris Jones, Institute of Cancer Research
One of the greatest medical success stories of the last century is the amazing growth in the survival from childhood cancer. Fifty years ago, only a quarter of children diagnosed with cancer survived. Today, more than 80 per cent of young patients can be successfully treated.
However, cancer still claims the lives of around 250 children every year in the UK. And unfortunately the children who survive may be left with serious health and developmental problems as a result of the intensive treatments used to save their young lives.
Through our investment in research, we are taking forward our understanding of childhood cancer, to give new insights into ways of treating young patients with even the most difficult forms of cancer. We hope to drive up the survival rate still further whilst reducing the risk of harm.